# US 2008/0188512 A1 · Treatment for irritable bowel syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188512 A1
- Document ID: US20080188512A1
- Status: Published application
- Kind: A1
- Application number: 12/027,564
- Filed: 2008-02-07
- Published: 2008-08-07
- Earliest claimed: 2007-02-07
- Assignees: Astellas Pharma Inc.
- Inventors: Ryuichi Takezawa; Hitoshi Doihara; Hiroyuki Ito; Jotaro Suzuki
- Web page: https://patentgrep.com/patent/US20080188512A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide is effective for treating IBS. In addition, IBS may be effectively treated with N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide when used concomitantly with at least one of various serotonin 5-HT3 receptor antagonists.

## Claims

### Claim 1

A method for treating IBS, which comprises administering an effective amount of N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide, a pharmaceutically acceptable salt thereof, or a solvate thereof to a patient in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, which comprises administering an effective amount of N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide sodium salt monohydrate to said patient in need thereof.

### Claim 3

A method for treating IBS, which comprises administering an effective amount of N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide, a pharmaceutically acceptable salt thereof, or a solvate thereof and at least one 5-HT3 receptor antagonist to a patient in need thereof.

### Claim 4 (depends on 3)

The method of claim 3, which comprises administering an effective amount of N-(1H-tetrazol-5-yl)-phenoxy-4H-quinolizin-4-one-3-carboxamide sodium salt monohydrate to said patient in need thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein said IBS is IBS with diarrhea.

### Claim 6 (depends on 2)

The method of claim 2, wherein said IBS is IBS with diarrhea.

### Claim 7 (depends on 3)

The method of claim 3, wherein said IBS is IBS with diarrhea.

### Claim 8 (depends on 4)

The method of claim 4, wherein said IBS is IBS with diarrhea.

### Claim 9 (depends on 1)

The method of claim 1, wherein said IBS is IBS with constipation.

### Claim 10 (depends on 2)

The method of claim 2, wherein said IBS is IBS with constipation.

### Claim 11 (depends on 3)

The method of claim 3, wherein said IBS is IBS with constipation.

### Claim 12 (depends on 4)

The method of claim 4, wherein said IBS is IBS with constipation.

### Claim 13 (depends on 1)

The method of claim 1, wherein said IBS is mixed IBS.

### Claim 14 (depends on 2)

The method of claim 2, wherein said IBS is mixed IBS.

### Claim 15 (depends on 3)

The method of claim 3, wherein said IBS is mixed IBS.

### Claim 16 (depends on 4)

The method of claim 4, wherein said IBS is mixed IBS.

### Claim 17

A composition, comprising:
(a) N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide, a pharmaceutically acceptable salt thereof, or a solvate thereof; and
(b) at least one 5-HT3 receptor antagonist.

### Claim 18 (depends on 17)

The composition of claim 17, wherein said at least one 5-HT3 receptor antagonist is at least one member selected from the group consisting of ramosetron, alosetron, and a mixture thereof.

### Claim 19 (depends on 17)

The composition of claim 17, which comprises N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide sodium salt monohydrate.
